Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

The 19th Congress of the European Hematology Association: Patients are Benefiting Today from Advances in Gene Therapy, Genome Sequencing, and New Drug Development

publication date: Jun 19, 2014
 | 
author/source: The European Hematology Association

It is now possible with gene therapy for patients with haemophilia to be free from severe bleeding in remarkable work that originated in animal studies.

EHAData about patients who remain free from the need for preventative injections for two years will be presented at the 19th Congress of the European Hematology Association. The understanding of how gene therapy technology might be applied to treat patients with other inherited diseases will also be discussed. Inherited bleeding tendency (haemophilia) can have devastating effects on the lives of patients and, if uncontrolled, can be life-threatening. Children and adults must receive injections of clotting factor proteins to prevent severe bleeding episodes, which in the long-term may deform joints resulting in significant physical disability.

Through collaborative global efforts, over 140 new genes have been identified that are important for the formation of red cells and platelets. These are likely to improve our understanding of a wide range of conditions, including very rare bleeding disorders due to defects involving platelets. At this year's Congress we will hear how knowledge of these genes will become integrated into clinical practice to benefit patients.

Blood that is too thick can lead to an excessive tendency to clot formation, particularly in veins in the legs and lungs, and can also lead to strokes. Patients have been treated with oral anti-clotting drugs (anti-coagulants) that require long-term monitoring and can be affected by food and other medications. This can result in frequent disruption to the lives of patients. Novel oral anti-coagulants (NOACs) are now available which do not require frequent long-term monitoring, and may also be safer. Results of clinical trials will be presented that help guide the selection of patient groups which may benefit from this true advance in patient care.

Press Registration for the 19th Congress of the European Hematology Association, June 12-15, 2014 in Milan, Italy. Registration for members of the press is free. 


more about european hematology association


 



 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events